Introduction: Esophageal Adenocarcinoma: Updates of Current Status

  • Alfred K. Lam
Part of the Methods in Molecular Biology book series (MIMB, volume 1756)


Esophageal and esophagogastric adenocarcinoma is highly prevalent in the Western populations and is a major cause of cancer-related morbidity and mortality worldwide. The incidence of esophageal adenocarcinoma is rapidly rising in the Western populations. The major predisposing diseases and pathogenesis (gastro-esophageal reflux disease, Barrett esophagus, and dysplasia) of the cancer are well known. There is an urgent need for works of the multidisciplinary teams (clinical, pathological, the molecular biology and translational research) for improved outcomes of patients with this cancer.

Key words

Esophageal adenocarcinoma Epidemiology Incidence Barrett esophagus Prognosis 


  1. 1.
    Lam KY, Ma L (1997) Pathology of esophageal cancers: local experience and current insights. Chin Med J 110:459–464PubMedGoogle Scholar
  2. 2.
    Rubenstein JH, Shaheen NJ (2015) Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology 149:302–317CrossRefGoogle Scholar
  3. 3.
    Runge TM, Abrams JA, Shaheen NJ (2015) Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 44: 203–231CrossRefGoogle Scholar
  4. 4.
    Lagergren J, Lagergren P (2013) Recent developments in esophageal adenocarcinoma. CA Cancer J Clin 63:232–248CrossRefGoogle Scholar
  5. 5.
    Butt J, Kandel G (2014) Barrett esophagus: when to endoscope. Clin Endosc 47:40–46CrossRefGoogle Scholar
  6. 6.
    Joo MK, Park JJ, Chun HJ (2018) Additional benefits of routine drugs on gastrointestinal cancer: statins, metformin, and proton pump inhibitors. Dig Dis 36:1–14CrossRefGoogle Scholar
  7. 7.
    Beales IL, Dearman L, Vardi I, Loke Y (2016) Reduced risk of Barrett’s esophagus in statin users: case-control study and meta-analysis. Dig Dis Sci 61:238–246CrossRefGoogle Scholar
  8. 8.
    Gharahkhani P, Fitzgerald RC, Vaughan TL et al (2016) Genome-wide association studies in esophageal adenocarcinoma and Barrett’s esophagus: a large-scale meta-analysis. Lancet Oncol 17:1363–1373CrossRefGoogle Scholar
  9. 9.
    Kadota T, Fujii S, Oono Y, Imajoh M, Yano T, Kaneko K (2016) Adenocarcinoma arising from heterotopic gastric mucosa in the cervical esophagus and upper thoracic esophagus: two case reports and literature review. Expert Rev Gastroenterol Hepatol 10:405–414CrossRefGoogle Scholar
  10. 10.
    Ning B, Abdelfatah MM, Othman MO (2017) Endoscopic submucosal dissection and endoscopic mucosal resection for early stage esophageal cancer. Ann Cardiothorac Surg 6:88–98CrossRefGoogle Scholar
  11. 11.
    Barnes JA, Willingham FF (2015) Endoscopic management of early esophageal cancer. J Clin Gastroenterol 49:638–646CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Cancer Molecular Pathology of School of MedicineGriffith UniversityGold CoastAustralia

Personalised recommendations